Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acasti Pharma Inc Announces Positive Phase II Open Label Clinical Trial Results


Tuesday, 13 Aug 2013 08:45am EDT 

Acasti Pharma Inc announced positive results for its Phase II 'randomized, open-label, dose-ranging, multi-center trial' designed to assess the safety and efficacy of its investigational new drug candidate CaPre in the treatment of mild to severe hypertriglyceridemia. 

Company Quote

0.44
0.0050 +1.15%
21 Nov 2014